Innova Medical Group distributed unapproved COVID-19 antigen tests and had quality-system and labeling violations, FDA says.
What happened
FDA inspected Innova Medical Group's device operations in Pasadena and Brea, California, from March 15 through April 9, 2021, and related Brea facilities from March 15 through April 8, 2021. FDA found the firm distributed its SARS-CoV-2 Antigen Rapid Qualitative Test in the United States without marketing approval, clearance, or authorization, and that 25T and 7T labeling made clinical performance claims not supported by the data. FDA also found current good manufacturing practice (CGMP) violations and noted that Emergency Use Authorization (EUA) clinical study data were identical to data other manufacturers had submitted.
What FDA found
Distributed the SARS-CoV-2 Antigen Rapid Qualitative Test in the U.S. without FDA marketing approval, clearance, or authorization.
21 U.S.C. § 351(f)(1)(B); 21 U.S.C. § 352(o)Labeling for the 25T and 7T configurations claimed clinical performance that FDA said was unsupported by or inconsistent with clinical data.
21 U.S.C. § 352(a)Failed to establish and maintain procedures for controlling and distributing finished devices or records showing devices were approved for release.
21 CFR § 820.160(a)Failed to establish acceptance procedures and records; test kits were not inspected or verified after arrival from the China contract manufacturer or before shipment, and some 7T and 3T boxes had the wrong Instructions for Use.
21 CFR § 820.80(a)Failed to establish procedures to identify, document, segregate, and disposition nonconforming product; 13 test-kit cartons were co-mingled with returned and damaged kits slated for destruction.
21 CFR § 820.90(a)Failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures.
21 CFR § 803.17
What FDA wants
FDA tells Innova to take immediate action to stop selling and distributing the unapproved COVID-19 tests and to email FDA within 48 hours with the steps taken. FDA also requires a written response within 15 business days on corrections to the quality-system and MDR violations.
Who should pay attention
- labs and schools using rapid COVID-19 antigen tests
- distributors and retailers selling INNOVA test kits
- contract manufacturers and suppliers of COVID-19 test components
This is a summary. Read the original letter on fda.gov.